IgGenix
IgGenix develops monoclonal antibodies to treat severe allergies and autoimmune diseases by targeting IgE antibodies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $40M
About
IgGenix develops monoclonal antibodies to treat severe allergies and autoimmune diseases by targeting IgE antibodies.
ImmunologyAntibodiesRare Disease
Funding History
1Total raised:$40M
Series B$40M